ESR1 and cancer: However, evidence to support the use of multigene profiles or other factors to guide the decision of selecting NACT is insufficient in ER-positive and HER2-negative cancers, and the general view is that NACT should only be considered if adjuvant chemotherapy is recommended irrespective of surgical pathology data1.